GSK’s Nuvalent acquisition brings two lead programs, each addressing different targets for non-small cell lung cancer. The Nuvalent lung cancer drugs are under FDA review and if they’re approved, GSK plans to launch both this year.
The post GSK Gets a Pair of Near-Commercial Lung Cancer Drugs via $10.6B Nuvalent Acquisition appeared first on MedCity News.
